New drug cocktail aims to control follicular lymphoma without chemo
NCT ID NCT07299149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people with untreated follicular lymphoma, a slow-growing blood cancer. The goal is to see how well the combo shrinks or eliminates tumors. About 34 adults with stage II bulky or stage III/IV disease will take part. This is not a cure, but aims to control the disease long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin 300020
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a targeted drug beat radiation for early-stage lymphoma?